<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02462044</url>
  </required_header>
  <id_info>
    <org_study_id>METC 13-1-033</org_study_id>
    <nct_id>NCT02462044</nct_id>
  </id_info>
  <brief_title>Contrast Enhancement on Coronary Computed Tomographic Angiography</brief_title>
  <acronym>EICAR</acronym>
  <official_title>Contrast Enhancement on Coronary Computed Tomographic Angiography : Effects on Intra-Coronary Attenuation Using Low Iodine Concentrations While Maintaining Identical IDR (EICAR-Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Computed tomographic angiography (CTA) is an important prognostic tool with regard to the
      detection of coronary artery stenoses. Both iodine delivery rate (IDR; the amount of iodine
      delivered to the patient per second) and iodine concentration are decisive factors in the
      opacification of arterial vessels.

      There remains to be some debate in the literature about whether the use of high iodine
      concentration contrast media is beneficial compared to lower iodine concentrations.

      To date, there have not been any studies comparing intracoronary attenuation using
      concentrated contrast media lower than 300 mg I/ml at coronary CTA. For a reliable comparison
      of CM with different iodine concentrations, adapted injection protocols insuring an identical
      IDR (in g iodine per second) are mandatory. The investigators hypothesize that usage of lower
      iodine concentrations, while maintaining identical IDR and total iodine load, will result in
      comparable diagnostical intra-vascular attenuation in CTA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate intravascular contrast enhancement and image quality in coronary CTA using
      different iodine concentrations ranging from 240 to 370 mg iodine per ml, administered with
      an identical IDR and total iodine load.

      To describe the effect of iodine concentration and flow rates on contrast bolus
      characteristics, eg time to peak, bolus homogeneity, injection pressure and patient comfort.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>intravascular contrast enhancement</measure>
    <time_frame>two years</time_frame>
    <description>intravascular contrast enhancement and image quality based on different contrast media (240, 300, 370) as measured by circular ROI in the target vessels using dedicated post processing.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>time to peak</measure>
    <time_frame>two years</time_frame>
    <description>Effect of iodine concentration - as measured by dedicated contrast monitoring software.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bolus homogeneity</measure>
    <time_frame>two years</time_frame>
    <description>Effect on contrast bolus characteristics and injection pressure - as measured by dedicated contrast monitoring software.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient comfort</measure>
    <time_frame>two years</time_frame>
    <description>Effect on patient comfort. As assessed by patient questionnaire.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Coronary Stenosis</condition>
  <arm_group>
    <arm_group_label>240</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 240 will receive CM with 240 mg Iodine/ml IDR 2.0 gI/s</description>
  </arm_group>
  <arm_group>
    <arm_group_label>300</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 300 will receive CM with 300 mg Iodine/ml IDR 2.0 gI/s</description>
  </arm_group>
  <arm_group>
    <arm_group_label>370</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 370 will receive CM with 370 mg Iodine/ml IDR 2.0 gI/s</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>240 mg Iodine</intervention_name>
    <arm_group_label>240</arm_group_label>
    <other_name>240 mg Iodine/ml IDR 2.0 gI/s</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>300 mg Iodine</intervention_name>
    <arm_group_label>300</arm_group_label>
    <other_name>300 mg Iodine/ml IDR 2.0 gI/s</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>370 mg Iodine</intervention_name>
    <arm_group_label>370</arm_group_label>
    <other_name>240 mg Iodine/ml IDR 2.0 gI/s</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Atypical or typical chest pain

        Exclusion Criteria:

          -  Unstable angina

          -  Hemodynamic instability

          -  History of CAD

          -  Pregnancy

          -  Renal insufficiency (defined as glomerular filtration rate (GFR) &lt;45ml/min or &lt;60ml
             +diabetes

          -  HR &gt; 90 bpm and the inability to receive beta-blockers and iodine allergy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <zip>6202AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.mumc.nl/patienten-en-bezoekers/specialisme/radiologie/over-radiologie</url>
  </link>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2014</study_first_submitted>
  <study_first_submitted_qc>June 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2015</study_first_posted>
  <last_update_submitted>January 4, 2016</last_update_submitted>
  <last_update_submitted_qc>January 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Maastricht University Medical Center</investigator_affiliation>
    <investigator_full_name>Marco Das</investigator_full_name>
    <investigator_title>Marco Das, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Computed tomography</keyword>
  <keyword>Coronary CTA</keyword>
  <keyword>Contrast media</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Stenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iodine</mesh_term>
    <mesh_term>Cadexomer iodine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

